Welcome to our dedicated page for IceCure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. is calling a remote Special General Meeting on August 6, 2026 to seek shareholder approval for amendments to certain outstanding Series B and Series C warrants issued in a March 2026 private placement.
The proposed changes would cut the warrants’ exercise price from $16.50 per share to $3.00 per share and extend their terms, so that Series B warrants would expire on June 18, 2031 and Series C warrants on June 18, 2027. The board states that lower exercise prices and longer durations are expected to increase the likelihood of exercise and potential capital inflows, and to keep the investor engaged with the company.
The company notes that these amendments may lead to the issuance of 20% or more of its outstanding share capital at terms not considered on-market under Israeli law, which is why shareholder approval by a simple majority at the meeting is required.
IceCure Medical Ltd. is registering for resale up to 5,500,002 ordinary shares by a selling shareholder, consisting of shares issuable upon exercise of Pre-Funded Warrants, Series D Warrants and Series E Warrants. The resale is by the selling shareholder; the company will not receive proceeds from those resales but will receive any cash proceeds upon exercise of the related warrants.
The prospectus describes resale methods, a June 17, 2026 private placement that issued 1,833,334 Pre-Funded Warrants, 1,833,334 Series D Warrants and 1,833,334 Series E Warrants and notes gross proceeds to the company of $5.5 million. Shares outstanding were 3,426,375 as of June 25, 2026.
IceCure Medical Ltd. reported that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq notified the company on June 18, 2026, after the closing bid price of IceCure’s ordinary shares was at least $1.00 per share for 10 consecutive business days from June 4 to June 17, 2026. With this, Nasdaq now considers the prior bid price deficiency matter closed, confirming the company’s continued listing under Nasdaq Listing Rule 5550(a)(2).
IceCure Medical Ltd. entered into a private placement with a single healthcare-focused institutional investor for approximately $5.5 million in gross proceeds. The company will issue 1,833,334 pre-funded warrants and accompanying Series D and Series E warrants, all exercisable immediately, with the warrants priced at $3.00 per share and the pre-funded warrants at a $2.9999 combined purchase price with warrants.
IceCure agreed to file a resale registration statement for the underlying ordinary shares and to short-term restrictions on additional equity offerings and variable-rate transactions, alongside 30-day lock-ups for directors and executives. The company plans to use net proceeds for working capital and general corporate purposes and separately reported a 70% increase in its active U.S. commercial ProSense® install base for breast cancer cryoablation following FDA marketing authorization.
IceCure Medical Ltd. is implementing a 1-for-30 reverse share split of its ordinary shares as part of efforts to regain compliance with Nasdaq’s $1.00 minimum bid price requirement and support its broader capital markets strategy. The shares will begin trading on a split-adjusted basis on June 4, 2026, while continuing to trade on the Nasdaq Capital Market under the symbol ICCM. The move was approved by shareholders at a special meeting on May 11, 2026, with the board later setting the 1-for-30 ratio. Issued and outstanding ordinary shares will be adjusted from 84,201,034 to approximately 2,806,701, without changing the authorized share capital of 2,500,000,000 ordinary shares. Fractional shares will be rounded to the nearest whole share, and proportional adjustments will be made to options, warrants, restricted shares, restricted share units, and share incentive plans.
IceCure Medical reports new clinical data on its ProSense® cryoablation system for kidney, breast, and benign breast tumors, presented at the ECIO 2026 conference. In the ICESECRET kidney cancer trial, cryoablation achieved an 89.4% recurrence-free rate in patients with tumors ≤3 cm, with 83.9% of patients recurrence-free at a median follow-up of 4.0 years.
Independent studies showed no residual cancer at 6 and 12 months in early-stage breast cancer patients and 100% excellent cosmetic outcomes, as well as a 92.9% reduction in fibroadenoma volume at 12 months. ProSense® is described as the first and only device with FDA marketing authorization for local treatment of low-risk breast cancer in women aged 70 and above with adjuvant endocrine therapy.